[go: up one dir, main page]

HUP0002175A1 - Xa-faktor inhibitorok alkalmazása önmagában vagy vérlemezkeaggregáció-gátló szerrel kombinálva artéria trombózis megelőzésére és kezelésére - Google Patents

Xa-faktor inhibitorok alkalmazása önmagában vagy vérlemezkeaggregáció-gátló szerrel kombinálva artéria trombózis megelőzésére és kezelésére

Info

Publication number
HUP0002175A1
HUP0002175A1 HU0002175A HUP0002175A HUP0002175A1 HU P0002175 A1 HUP0002175 A1 HU P0002175A1 HU 0002175 A HU0002175 A HU 0002175A HU P0002175 A HUP0002175 A HU P0002175A HU P0002175 A1 HUP0002175 A1 HU P0002175A1
Authority
HU
Hungary
Prior art keywords
treating
combined
factor inhibitors
preventing arterial
arterial thromboembolism
Prior art date
Application number
HU0002175A
Other languages
English (en)
Inventor
André Bernat
Jean-Marc Herbert
Maurice Petitou
Ronald Van Amsterdam
Original Assignee
Akzo Nobel N.V.
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V., Sanofi Synthelabo filed Critical Akzo Nobel N.V.
Publication of HUP0002175A1 publication Critical patent/HUP0002175A1/hu
Publication of HUP0002175A3 publication Critical patent/HUP0002175A3/hu
Publication of HU227956B1 publication Critical patent/HU227956B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya Xa faktor antitrombin III útján ható direkt vagyindirekt szelektív inhibitorainak alkalmazása önmagában vagy egy vagytöbb vérlemezkeaggregáció-gátló hatású vegyülettel kombinálva artériástromboembóliás betegségek kezelésére és megelőzésére szolgálógyógyszerek előállítására. A találmány az említett kombinációttartalmazó gyógyszerkészítményeket is magában foglalja. Ó
HU0002175A 1997-06-13 1998-06-09 Use of factor xa inhibiting oligosaccharide with a platelet antiaggregating agent for treating arterial thrombosis HU227956B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
PCT/FR1998/001172 WO1998056365A1 (fr) 1997-06-13 1998-06-09 INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE

Publications (3)

Publication Number Publication Date
HUP0002175A1 true HUP0002175A1 (hu) 2000-11-28
HUP0002175A3 HUP0002175A3 (en) 2003-05-28
HU227956B1 HU227956B1 (en) 2012-07-30

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002175A HU227956B1 (en) 1997-06-13 1998-06-09 Use of factor xa inhibiting oligosaccharide with a platelet antiaggregating agent for treating arterial thrombosis

Country Status (42)

Country Link
US (2) US6541488B1 (hu)
EP (1) EP0986376B1 (hu)
JP (1) JP3988803B2 (hu)
KR (1) KR100598451B1 (hu)
CN (1) CN1253150C (hu)
AR (1) AR012247A1 (hu)
AT (1) ATE384528T1 (hu)
AU (1) AU728826B2 (hu)
BR (1) BR9810520A (hu)
CA (1) CA2293415C (hu)
CO (1) CO4940476A1 (hu)
CY (1) CY1107912T1 (hu)
CZ (1) CZ299518B6 (hu)
DE (1) DE69839046T2 (hu)
DK (1) DK0986376T3 (hu)
DZ (1) DZ2512A1 (hu)
EE (1) EE04737B1 (hu)
ES (1) ES2299209T3 (hu)
FR (1) FR2764511B1 (hu)
GT (1) GT199800171A (hu)
HR (1) HRP980322B1 (hu)
HU (1) HU227956B1 (hu)
ID (1) ID29309A (hu)
IL (1) IL133452A (hu)
IS (1) IS2619B (hu)
ME (1) ME00685B (hu)
MY (1) MY124648A (hu)
NO (1) NO323739B1 (hu)
NZ (1) NZ501452A (hu)
PL (1) PL193405B1 (hu)
PT (1) PT986376E (hu)
RS (1) RS49902B (hu)
RU (1) RU2212886C2 (hu)
SA (1) SA98190552B1 (hu)
SI (1) SI0986376T1 (hu)
SK (1) SK286311B6 (hu)
TR (1) TR199903087T2 (hu)
TW (1) TW565442B (hu)
UA (1) UA70919C2 (hu)
UY (1) UY25044A1 (hu)
WO (1) WO1998056365A1 (hu)
ZA (1) ZA985137B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
WO2004031143A2 (en) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
CA2507026A1 (en) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical COMBINED MEDICINES
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
CA2553434C (en) * 2004-04-23 2012-08-07 Sumitomo Electric Industries, Ltd. Coding method for motion-image data, decoding method, terminal equipment executing these, and two-way interactive system
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
AU2006301240A1 (en) * 2005-10-10 2007-04-19 Msd Oss B.V. Antithrombotic compound
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
CA2966249C (en) * 2014-10-30 2019-06-18 Chengdu Baiyu Pharmaceutical Co., Ltd. Pharmaceutical composition containing ginkgolide b and xa factor inhibitor, preparation method thereof and use thereof
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE419871B (sv) * 1975-12-01 1981-08-31 Pharmacia Ab Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
RU2045264C1 (ru) * 1983-12-15 1995-10-10 Белорусский научно-исследовательский институт кардиологии Антиагрегационное средство
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
EA002475B1 (ru) 1996-11-27 2002-06-27 Авентис Фармасьютикалз Продактс Инк. Фармкомпозиция, содержащая соединения с анти-ха активностью и соединения антагониста агрегации тромбоцитов, их применение, набор, содержащий эти соединения, способ лечения или профилактики заболеваний, сопутствующих тромбообразованию
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
CZ299518B6 (cs) 2008-08-20
RS49902B (sr) 2008-08-07
MY124648A (en) 2006-06-30
DZ2512A1 (fr) 2003-02-01
PT986376E (pt) 2008-04-01
EP0986376B1 (fr) 2008-01-23
HK1032750A1 (en) 2001-08-03
DK0986376T3 (da) 2008-05-13
KR100598451B1 (ko) 2006-07-10
WO1998056365A1 (fr) 1998-12-17
GT199800171A (es) 2000-04-21
DE69839046T2 (de) 2009-01-15
AR012247A1 (es) 2000-09-27
IS2619B (is) 2010-05-15
IS5280A (is) 1999-11-30
KR20010013690A (ko) 2001-02-26
EE04737B1 (et) 2006-12-15
EE9900574A (et) 2000-08-15
YU63699A (sh) 2002-06-19
HRP980322A2 (en) 1999-04-30
NO996137L (no) 2000-02-14
CN1253150C (zh) 2006-04-26
NZ501452A (en) 2002-06-28
CY1107912T1 (el) 2013-09-04
HUP0002175A3 (en) 2003-05-28
NO996137D0 (no) 1999-12-10
ME00685B (me) 2008-08-07
ZA985137B (en) 1999-01-07
AU728826B2 (en) 2001-01-18
BR9810520A (pt) 2000-09-19
HU227956B1 (en) 2012-07-30
TW565442B (en) 2003-12-11
RU2212886C2 (ru) 2003-09-27
SA98190552B1 (ar) 2006-09-09
SK286311B6 (en) 2008-07-07
CO4940476A1 (es) 2000-07-24
JP3988803B2 (ja) 2007-10-10
CA2293415C (en) 2011-08-09
TR199903087T2 (xx) 2000-05-22
AU7924698A (en) 1998-12-30
PL337288A1 (en) 2000-08-14
CA2293415A1 (en) 1998-12-17
EP0986376A1 (fr) 2000-03-22
FR2764511A1 (fr) 1998-12-18
ES2299209T3 (es) 2008-05-16
IL133452A0 (en) 2001-04-30
IL133452A (en) 2004-09-27
DE69839046D1 (de) 2008-03-13
SI0986376T1 (sl) 2008-06-30
PL193405B1 (pl) 2007-02-28
US6541488B1 (en) 2003-04-01
SK170999A3 (en) 2000-07-11
HRP980322B1 (en) 2003-12-31
CZ446099A3 (cs) 2000-04-12
CN1274281A (zh) 2000-11-22
FR2764511B1 (fr) 2000-09-08
US20040092477A1 (en) 2004-05-13
UY25044A1 (es) 2000-10-31
UA70919C2 (uk) 2004-11-15
JP2002504110A (ja) 2002-02-05
ATE384528T1 (de) 2008-02-15
ID29309A (id) 2001-08-16
NO323739B1 (no) 2007-07-02

Similar Documents

Publication Publication Date Title
HUP0002175A1 (hu) Xa-faktor inhibitorok alkalmazása önmagában vagy vérlemezkeaggregáció-gátló szerrel kombinálva artéria trombózis megelőzésére és kezelésére
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
ME00578A (en) Use of gastrointestinal lipase inhibitors
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
AR021535A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
FI941826A0 (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
FI971207L (fi) Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
NO20021784L (no) Anvendelse av dipyridamol eller mopidamol for fremstilling av et medikament for behandling og forebygging av fibrin-avhengigmikrosirkulasjonsforstyrrelser
NO993670D0 (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikament for behandling av AIDS
NO975234D0 (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
NO960775D0 (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
EP0617956A3 (en) Piroxicam containing analgesic anti-inflammatory patch.
FI973185L (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
MX9405371A (es) Derivado de naftilo.
HUP9801075A2 (hu) Kombinált állandó dózisú angiotenzint átalakító enzim inhibítor kalciumcsatorna-antagonista, eljárás ennek előállítására, valamint alkalmazása szív- és érrendszeri betegségek kezelésében
NO990949D0 (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS